Summit Therapeutics financials
$16.39+5.88%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$220.5M | -$195.2M | -$224.9M | -$234.2M | -$568.4M | -$66.9M | -$65.6M | -$58.4M | -$59.6M | -$42.4M | -$36.2M | -$20.5M |
| Net income | -$215.7M | -$189.4M | -$219.2M | -$231.8M | -$565.9M | -$62.9M | -$61.2M | -$56.3M | -$60.4M | -$43.5M | -$36.6M | -$21.3M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.28 | $-0.24 | $-0.29 | $-0.31 | $-0.76 | $-0.09 | $-0.08 | $-0.08 | $-0.09 | $-0.06 | $-0.05 | $-0.03 |
| EBITDA | -$220.4M | -$195.2M | -$224.9M | -$234.2M | -$568.4M | -$66.8M | -$80.6M | -$58.4M | -$59.6M | -$42.4M | -$557.1M | -$20.5M |
| Operating cash flow | -$141.1M | -$122.3M | -$101.9M | -$93.1M | -$66.7M | -$61.2M | -$48.7M | -$30.3M | -$33.0M | -$30.1M | -$19.5M | -$14.9M |
| Free cash flow | -$142.0M | -$122.5M | -$102.1M | -$93.2M | -$66.7M | -$61.6M | -$48.7M | -$30.4M | -$33.1M | -$30.1M | -$19.5M | -$14.9M |
| Diluted shares | 778.2M | 775.5M | 766.7M | 743.4M | 742.6M | 738.1M | 737.8M | 726.7M | 707.9M | 701.8M | 705.0M | 697.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $419.4M | $106.5M | $225.3M | $238.6M | $297.9M | $211.5M |
| Short-term investments | $271.3M | $492.2M | $488.2M | $0.00 | $0.00 | $149.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $752.2M | $647.9M | $751.2M | $261.7M | $324.0M | $383.8M |
| Total liabilities | $122.2M | $101.9M | $92.3M | $69.5M | $64.6M | $39.5M |
| Shareholders' equity | $630.0M | $545.9M | $658.9M | $192.3M | $259.4M | $344.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology